Aptevo Therapeutics enters $25M standby equity purchase agreement with Yorkville

Aptevo Therapeutics Inc.

Up to $25M in common stock may be sold to YA II PN over 36 months at 96% of lowest 3-day VWAP.
Exchange cap of 151,755 shares (19.99% of outstanding) unless stockholder approval or avg price ≥ $3.66.
Yorkville's beneficial ownership limited to 9.99% of outstanding shares.
Structuring fee of $25,000 paid; commitment fee of 2% of commitment amount in five quarterly installments.
Advance subject to filing and effectiveness of registration statement with the SEC.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.